Idiopathic Short Stature
Pipeline by Development Stage
Competitive Landscape
11 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (13)
Total enrollment: 1,720 patients across 13 trials
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)
Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature
Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
A Trial of YPEG-rhGH in Children With Short Stature
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.